Irritable Bowel Syndrome Treatment Market | Asia-Pacific region would exhibit the highest CAGR of 9.9% during 2019-2026

Posted by supriya on August 9th, 2022

According to a new report published by Allied Market Research, titled, "Antihyperlipidemic Drugs Market by Drug Class: Global Opportunity Analysis and Industry Forecast, 2019-2026," the global antihyperlipidemic drugs market was valued at ,456 million in 2018, and is expected to reach ,865 million by 2026, registering a CAGR of 7.5% from 2019 to 2026.

The rise in level of lipids in the blood is called as hyperlipidemia. The drugs that are used to treat the condition are called antihyperlipidemic drugs. Furthermore, there are major complications associated with this condition such as heart attack. Therefore, the condition requires early monitoring and treatment. Some of the antihyperlipidemic drugs available in the market include statins, bile acid sequestrants, cholesterol, and others.

 


Do Enquiry for Sample Report @ https://www.alliedmarketresearch.com/request-sample/6284

The rise in level of lipids in the blood is called as hyperlipidemia. The drugs that are used to treat the condition are called antihyperlipidemic drugs. Furthermore, there are major complications associated with this condition such as heart attack. Therefore, the condition requires early monitoring and treatment. Some of the antihyperlipidemic drugs available in the market include statins, bile acid sequestrants, cholesterol, and others.

According to drug class, statins occupied the largest antihyperlipidemic drugs market share in 2018, owing to surge in the incidence of cardiovascular disorders. Furthermore, statins reduce the risk associated with heart attacks, which is another major factor that contributes to the growth of the market. Moreover, PCSK9 inhibitors segment is expected to register the fastest growth during the forecast period, owing to the benefits offered such as drastic reduction of LDL levels in the blood. The other factors that boost the growth of the market include the surge in the geriatric population and rise in healthcare expenditure across the globe. In addition, the other factors which boost the growth of the market include the additional benefits offered by the statins such as improved endothelial function, enhance the stability of atherosclerotic plaques, and reduce the amount of inflammation & damage done to cells due to oxidative stress.

The developing economies offer lucrative opportunities for antihyperlipidemic drugs providers to expand their business. The constantly evolving life science industry drives the growth of the market in the developing economies such as India, China, and others. Furthermore, this report entails a detailed quantitative analysis along with the current global antihyperlipidemic drugs market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.

Key Findings of the Study:

Statins occupied one-third share of the global antihyperlipidemic drugs market in 2018.
The PCSK9 inhibitors segment is anticipated to grow with the highest CAGR throughout the forecast period.
The cholesterol absorption inhibitors segment accounted for more than one-fourth share of the market in 2018.
Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAME
Key Market Segments

By Drug Class
Statins
Bile Acid Sequestrants
Cholesterol Absorption Inhibitors
Fibric Acid Derivatives
PCSK9 Inhibitors
Combination
Others

Get Customized Report @ https://www.alliedmarketresearch.com/request-for-customization/6284

Key Market Players

ABBVIE INC.
Amgen Inc.
AstraZeneca plc
Bristol-Myers Squibb Company
Daiichi Sankyo Company, Limited
Dr. Reddy's Laboratories Ltd
Merck & Co., Inc
Mylan N.V
Pfizer Inc.
SANOFI S.A.

According to a new report published by Allied Market Research, titled, "Irritable Bowel Syndrome Treatment Market by Type, Product, and End User: Global Opportunity Analysis and Industry Forecast, 2019-2026," the global irritable bowel syndrome treatment market size was valued at $ 1,071 million in 2018, and is projected to reach ,012 million by 2026, growing at a CAGR of 8.2% from 2019 to 2026.

Irritable bowel syndrome is a gastrointestinal tract (GT) illness with the symptoms such as alteration of bowel habits and severe abdominal pain. Usually, the digested food passes through the gastrointestinal tract (GT) and the movement of food is due to intestinal muscle contraction. The irritable bowel syndrome hinders natural movements of that muscle; thus, food material cannot pass through the digestive tract and may result in abdominal pain, diarrhea, mucus in the stool, constipation, bloating & gas, and cramping. The Centers for Disease Control and Prevention (CDC) suggested that nearly 3 million people in the U.S. were reported being treated with irritable bowel syndrome in 2015. The irritable bowel syndrome can be treated by making changes by proper medication, making changes in daily diet, and reducing stress.

 


Do Enquiry for Sample Report @ https://www.alliedmarketresearch.com/request-sample/6313

Key Findings of the Study:

Based on type, the IBS with diarrhea (IBS-D) segment held 47.76% share in the global market in 2018.
Based on product, the rifaximin segment accounted for the largest irritable bowel syndrome treatment market share in 2018 and is expected to remain dominant throughout the forecast period.
Based on end user, the drug stores & retail pharmacies segment held 54.01% share in the global market in 2018.
Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 9.9% during the forecast period.

In 2018, North America accounted for the major share in the irritable bowel syndrome market size and is expected to continue this trend, owing to availability of well-developed infrastructure facilities, presence of majority of the key players, rise in gastrointestinal diseases, and huge availability of trained medical professionals. On the other hand, Asia-Pacific is estimated to register the fastest growth during the forecast period, owing to rise in disposable income, high population base, surge in the geriatric population, and increase in patient awareness toward irritable bowel syndrome treatment.

The major factors that boost the growth of the global irritable bowel syndrome treatment market are adoption of sedentary lifestyle, rise in level of stress, unhealthy diet, rise in geriatric population, surge in prevalence of gastrointestinal diseases and disorders such as alteration of bowel habit, & abdominal pain, increase in awareness programs for irritable bowel syndrome treatment, and launches of various developed pipeline drugs for the irritable bowel syndrome treatment during the forecast period. Moreover, increase in prevalence of irritable bowel syndrome in female is expected to further drive the growth of the global irritable bowel treatment market. However, lack of specific treatment which treat all the symptoms of this disorder, and high competition among the key players related to pricing are expected to restrain the irritable bowel syndrome treatment market growth.

 Key Market Segments

By Type
IBS with Diarrhea (IBS-D)
IBS with Constipation (IBS-C)
Mixed-presentation IBS (IBS-M)
By Product
Rifaximin
Eluxadoline
Lubiprostone
Linaclotide
Others

Key Market Players

Abbott Laboratories
Allergan plc
Ardelyx Inc.
Astellas Pharma Inc.
AstraZeneca plc
GlaxoSmithKline Plc
Johnson & Johnson (McNeil Consumer Healthcare)
Novartis AG
Sebela Pharmaceuticals Inc.
Takeda Pharmaceutical Company Ltd.

Get Customized Report @ https://www.alliedmarketresearch.com/request-for-customization/6313

Like it? Share it!


supriya

About the Author

supriya
Joined: July 12th, 2022
Articles Posted: 49

More by this author